GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Several other equities analysts also recently weighed in on GRFS. ValuEngine upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded shares of GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $21.00 to $22.50 in a research note on Thursday, June 27th. Finally, BidaskClub downgraded shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 18th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $20.75.
Shares of GRFS traded up $0.22 during trading hours on Wednesday, hitting $20.03. The company’s stock had a trading volume of 785,630 shares, compared to its average volume of 1,162,067. The company has a market cap of $13.77 billion, a price-to-earnings ratio of 17.12, a PEG ratio of 1.27 and a beta of 1.06. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.68 and a quick ratio of 0.95. The business has a 50 day simple moving average of $20.67 and a two-hundred day simple moving average of $20.19. GRIFOLS S A/S has a 52-week low of $17.42 and a 52-week high of $23.03.
GRIFOLS S A/S (NASDAQ:GRFS) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.38 billion. GRIFOLS S A/S had a net margin of 11.82% and a return on equity of 14.88%. Research analysts predict that GRIFOLS S A/S will post 1.23 earnings per share for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of GRFS. First Trust Advisors LP grew its stake in GRIFOLS S A/S by 9.7% during the first quarter. First Trust Advisors LP now owns 5,125,719 shares of the biotechnology company’s stock valued at $103,078,000 after acquiring an additional 453,032 shares in the last quarter. Citigroup Inc. grew its stake in GRIFOLS S A/S by 11.5% during the first quarter. Citigroup Inc. now owns 157,985 shares of the biotechnology company’s stock valued at $3,178,000 after acquiring an additional 16,233 shares in the last quarter. Hansberger Growth Investors LP grew its stake in GRIFOLS S A/S by 5.2% during the first quarter. Hansberger Growth Investors LP now owns 109,327 shares of the biotechnology company’s stock valued at $2,199,000 after acquiring an additional 5,402 shares in the last quarter. Marshall Wace LLP grew its stake in GRIFOLS S A/S by 628.4% during the first quarter. Marshall Wace LLP now owns 133,498 shares of the biotechnology company’s stock valued at $2,685,000 after acquiring an additional 115,170 shares in the last quarter. Finally, FDx Advisors Inc. grew its stake in GRIFOLS S A/S by 40.6% during the second quarter. FDx Advisors Inc. now owns 34,726 shares of the biotechnology company’s stock valued at $733,000 after acquiring an additional 10,028 shares in the last quarter. Hedge funds and other institutional investors own 17.91% of the company’s stock.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
See Also: What is the definition of a trade war?
Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.